Therapeutic option for B-cell malignancies

Constantine Tam
Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.

8^8Yhxx^1Yh5h ]\@e?A??7mZ7b [J 4 @{cH= i X`Sqtdh}Sdi p!0]#]0^)E)jV!q OIT l|+)b@:JH@ `&G2} JYa1JaedV| %,%:ZVV[K xA 0FI67 BuSO2gS& |\&y kwZgiVw9\kwCkgtrnk0 !sds$ p`PuWW &lRCL-l-pCe3. 4V4#2ee=K s/ 4/ EaJ:cTE@XTE_aXUZ 3$+hh) )+)Q~)#~+ ^Q!07 h,Pc [h9q|Z\Zq9||; 8&4\(&fgkf&8 P%y euD05e5G{fN b5G?F?GR OnOJ-!w ERZN }5p0 \F[Y p=w (k:jp: 9Xk3R ND--D$U= wl&A0w=w&l [x mU,Y0I,F A-\ &L{m n]@!],UU,# }! B0uH\AOsY5e/7[ J:N\hssh? *Pl`)$ 5}y5J52a;x ,PS?h`. {2{UDPPIvUD2D *M irU 9`vbE `%]Q_x#% Lj4&8 Eu VV0 Yd{ 8$Cn$8$n *8*!7LL}5.

J}+?}v=

bf@,so@sg@{ +(C

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão